Walleye Capital
VNDA icon

Walleye Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Walleye Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.6K Buy
+12,359
New +$80.7K ﹤0.01% 4032
2025
Q3 		– Sell
-94,298
Closed -$445K – 5170
2025
Q2 		$445K Buy
94,298
+57,332
+155% +$251K ﹤0.01% 2743
2025
Q1 		$170K Buy
+36,966
New +$172K ﹤0.01% 3383
2024
Q2 		– Sell
-19,018
Closed -$78.2K – 6044
2024
Q1 		$78.2K Sell
19,018
-86,736
-82% -$347K ﹤0.01% 4514
2023
Q4 		$446K Sell
105,754
-152,193
-59% -$614K ﹤0.01% 3034
2023
Q3 		$1.11M Sell
257,947
-43,284
-14% -$240K ﹤0.01% 2172
2023
Q2 		$1.99M Sell
301,231
-14,138
-4% -$90.6K 0.01% 1337
2023
Q1 		$2.14M Buy
315,369
+168,329
+114% +$1.18M 0.03% 683
2022
Q4 		$1.09M Buy
+147,040
New +$1.43M 0.02% 954
2022
Q3 		– Sell
-194,164
Closed -$2.12M – 3570
2022
Q2 		$2.12M Buy
194,164
+130,114
+203% +$1.35M 0.06% 348
2022
Q1 		$724K Sell
64,050
-44,441
-41% -$584K 0.02% 804
2021
Q4 		$1.7M Buy
+108,491
New +$1.89M 0.05% 372

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's VNDA Position: Q2 2026 in Review

Walleye Capital opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 12,359 shares worth $75.6K. The stake represents ﹤0.01% of the portfolio and ranks #4032 among its holdings. This is a return to the name: Walleye Capital previously reported a position in VNDA as recently as Q2 2025.

Walleye Capital first reported a position in VNDA in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.14M in Q1 2023. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Walleye Capital held 12,359 shares of Vanda Pharmaceuticals worth $75.6K as of Q2 2026.
  • Vanda Pharmaceuticals was a new Walleye Capital position in Q2 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4032 holding.
  • Walleye Capital first reported a position in Vanda Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • Walleye Capital's Vanda Pharmaceuticals position peaked at $2.14M in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.